Note: Supplemental materials are not guaranteed with Rental or Used book purchases.
Purchase Benefits
What is included with this book?
Preface | p. v |
Contributors | p. xi |
Color Plates | p. xv |
Trends in Prostate Cancer Screening | |
Overview of US Prostate Cancer Trends in the Era of PSA Screening | p. 3 |
Trends in Prostate Cancer Screening: Overview of the UK | p. 15 |
Trends in Prostate Cancer Screening: Canada | p. 23 |
Trends in Prostate Cancer Screening - Overview of Europe | p. 35 |
Prostate-Specific Antigen | |
Evolution of Prostate-Specific Antigen for Screening | p. 51 |
The Performance Characteristics of Prostate-Specific Antigen for Prostate Cancer Screening | p. 61 |
The Performance of PSA for Predicting Prostate Cancer After a Prior Negative Prostate Biopsy | p. 71 |
Subfractions and Derivatives of Total Prostate-Specific Antigen in the Early Detection of Prostate Cancer | p. 79 |
PSA Velocity at Presentation as a Predictor of Prostate Cancer Aggressiveness | p. 97 |
Risk Assessment for Prostate Cancer | |
Nomograms for Prostate Cancer | p. 117 |
Decision Aid Criteria and Artificial Neural Networks for Optimizing Prostate Cancer Risk Prediction | p. 181 |
Development of the Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator | p. 195 |
Integration of Risk Assessment in Prostate Cancer Screening | p. 205 |
Family History of Prostate Cancer During Rapidly Increasing Incidence | p. 213 |
Recent Biomarkers for Prostate Cancer | |
PSA Isoforms: [-2]proPSA Significant Adjunct to Free PSA | p. 225 |
PCA3 | |
Transcriptional Profiling of Prostate Cancer: Biomarker Identification and Clinical Applications | p. 243 |
Biomarkers for Prostate Cancer Detection: Family-Based Linkage Analysis and Case-Control Association Studies | p. 261 |
GSTPI Hypermethylation for Prostate Cancer Detection | p. 279 |
EPCA and EPCA-2 as Potential Biomarkers for Prostate Cancer Detection | p. 289 |
Design and Methodologic Considerations in Biomarker Studies | |
Toward a Robust System for Biomarker Triage and Validation - EDRN Experience | p. 297 |
Statistical Evaluation of Markers and Risk Tools for Prostate Cancer Classification and Prediction | p. 307 |
Pitfalls in Prostate Cancer Biomarker Evaluation Studies | p. 319 |
Building upon Recently Completed and Ongoing Prospective Trials | |
Prostate-Specific Antigen and Its Role on the Prostate Cancer Prevention Trial | p. 333 |
The Selenium and Vitamin E Cancer Prevention Trial | p. 349 |
PLCO: A Randomized Controlled Screening Trial for Prostate, Lung, Colorectal, and Ovarian Cancer | p. 361 |
The European Randomized Study of Screening for Prostate Cancer (ERSPC) | p. 373 |
Index | p. 387 |
Table of Contents provided by Ingram. All Rights Reserved. |
The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.